Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 25Stomach Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Colonic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Neoplasms 1Neoplasm, Residual 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Metastatic Colorectal Adenocarcinoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Hodgkin Disease 1HER2-positive Colorectal Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastric Cancer Adenocarcinoma Metastatic 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Breast Neoplasms 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1Advanced Malignancies 1Advanced Colorectal Cancer 1

Interventions

trifluridine tipiracil drug combination 1regorafenib 1defactinib 1Oxaliplatin 1HMPL-013 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Colorectal Cancer × HMPL-013 × 1 year × Clear all
NCT06199973 2025-07-17

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Active not recruiting
130 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡